The DMD Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma epithelial cell line. This product features targeted disruption of the DMD gene, which encodes dystrophin, a large cytoskeletal protein essential for linking the actin cytoskeleton to the extracellular matrix. The polyclonal format provides a heterogeneous pool of cells with DMD gene inactivation, enabling robust loss-of-function studies without single-cell cloning artifacts. Researchers can utilize these cells to investigate dystrophin biology in a well-characterized epithelial background.
The A-549 host cell line, originally isolated from the lung adenocarcinoma of a 58-year-old Caucasian male, serves as a widely accepted model of human alveolar type II epithelial cells. These adherent cells are extensively employed in cancer biology, respiratory research, viral infection studies, and drug metabolism assays due to their well-documented characteristics and genetic stability. The A-549 background offers a reproducible platform for exploring dystrophin function outside the traditional muscle context, where its roles in cell adhesion and signaling can be dissected.
Dystrophin functions as a central scaffold within the dystrophin-glycoprotein complex (DGC), anchoring F-actin to ??-dystroglycan and the extracellular ??-dystroglycan. The DMD locus is transcriptionally regulated by MYOD1, MEF2, Sp1, and SRF. Dystrophin interacts with actin, syntrophins, dystrobrevin, and nNOS, while its C-terminus binds ??-dystroglycan, linking to the matrix via ??-dystroglycan and sarcoglycans. Disruption impairs nNOS localization and downstream effectors such as the sodium/calcium exchanger and MAPK/ERK signaling, affecting calcium homeostasis and mechanotransduction.
In the A-549 epithelial context, DMD knockout models dystrophin’s non-contractile roles, including contributions to cell-extracellular matrix adhesion and epithelial integrity. Loss of the DGC compromises membrane stability, calcium regulation, and signaling pathways, permitting investigation of dystrophin function independent of muscle-specific machinery. This system also facilitates studies of altered adhesion and mechanosensing in cancer cells, where dystrophin’s scaffolding role may influence progression.
Applications include modeling Duchenne muscular dystrophy pathways in non-muscle cells, screening for dystrophin restoration compounds, and examining mechanisms of membrane repair and calcium flux. Standard assays encompass western blotting, RT-qPCR, immunofluorescence, adhesion assays, calcium imaging, and migration/invasion analyses. For additional details, contact Ascent Research.
